The National Company Law Tribunal (NCLT), Bengaluru Bench, has sanctioned the amalgamation of Shilpa Therapeutics Private Limited, a wholly owned subsidiary, with Shilpa Medicare Limited. The order dated 27 February 2026 makes the scheme binding, subject to filing certified copies with the Registrar of Companies and fulfilling statutory conditions.
Shilpa Medicare Limited has announced that the Hon’ble NCLT, Bengaluru Bench, has approved the merger of its wholly owned subsidiary, Shilpa Therapeutics Private Limited, with the parent company. This amalgamation, filed under Sections 230 to 232 of the Companies Act, 2013, aims to streamline operations and strengthen the company’s healthcare innovation strategy.
Key Highlights
-
The scheme was sanctioned by NCLT on 27 February 2026 after due compliance with shareholder and creditor approvals
-
Shilpa Therapeutics, being a wholly owned subsidiary, will merge without any share issuance, with existing shares cancelled
-
The appointed date for the scheme has been revised to 1 April 2025, aligning with tribunal directions
-
All employees of Shilpa Therapeutics will be absorbed into Shilpa Medicare, ensuring continuity of service and safeguarding staff interests
-
The company has undertaken to settle statutory dues, MSME obligations, and comply with FEMA/RBI regulations on foreign transactions
-
The merger will come into effect once certified copies of the order are filed with the Registrar of Companies and other conditions are met
This development marks a significant step in Shilpa Medicare’s consolidation strategy, enhancing operational efficiency and reinforcing its commitment to affordable healthcare innovation.
Source: Shilpa Medicare Limited filing with BSE and NSE, NCLT Bengaluru Bench order dated 27 February 2026.